MAPK12
MOLECULAR TARGETmitogen-activated protein kinase 12
MAPK12 (mitogen-activated protein kinase 12) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAPK12
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | sb 203580 | 4.92 | 136 |
| 2 | foretinib | 4.34 | 76 |
| 3 | doramapimod | 4.06 | 57 |
| 4 | quizartinib | 3.99 | 53 |
| 5 | sb 202190 | 3.64 | 37 |
| 6 | tae 684 | 3.43 | 30 |
| 7 | linifanib | 3.33 | 27 |
| 8 | sp 600125 | 3.22 | 24 |
| 9 | lestaurtinib | 3.04 | 20 |
| 10 | r 406 | 2.83 | 16 |
| 11 | ast 487 | 2.56 | 12 |
| 12 | Sorafenib | 1.61 | 4 |
| 13 | Anisomycin | 0.69 | 1 |
| 14 | isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from | 0.69 | 1 |
| 15 | sp600125 | 0.69 | 1 |
| 16 | withaferin | 0.69 | 1 |
About MAPK12 as a Drug Target
MAPK12 (mitogen-activated protein kinase 12) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented MAPK12 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAPK12 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.